Publication at Second Faculty of Medicine, Third Faculty of Medicine |
2005
Abstract
Based on the assessment of the effectiveness and safety after approval by the competent institutions of the European Union, the State Institute for Drug Control and universal health insurance CR is currently the treatment of growth hormone indicated for the following five indication groups of pediatric patients: 1 Growth hormone deficiency, 2 Turner's syndrome, 3 Growth failure due to chronic renal insufficiency, 4 Prader-Willi syndrome, 5 Postnatal growth failure following the intrauterine growth retardation